TRIM24 and cancer: Fifteen anti-TIF1-Ab-positive cases were <39 years of age at DM onset and none developed cancer during the follow-up period, whereas 21 (53%) of the 40 anti-TIF1-Ab-positive cases ≥39 years of age at DM onset developed cancer during the follow-up period.